Aprogen Medicines Inc. (KRX:007460)
South Korea
· Delayed Price · Currency is KRW 751.00
-1.00 (-0.13%)
Last updated: Mar 27, 2025
Aprogen Medicines Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 150,114 | 150,578 | 78,349 | 26,296 | 127,143 | Upgrade
|
| Other Revenue | - | -0 | -0 | 0 | - | Upgrade
|
| Revenue | 150,114 | 150,578 | 78,349 | 26,296 | 127,143 | Upgrade
|
| Revenue Growth (YoY) | -0.31% | 92.19% | 197.95% | -79.32% | 62.48% | Upgrade
|
| Cost of Revenue | 115,818 | 116,380 | 78,143 | 31,513 | 93,148 | Upgrade
|
| Gross Profit | 34,295 | 34,198 | 205.9 | -5,217 | 33,994 | Upgrade
|
| Selling, General & Admin | 52,138 | 66,149 | 67,621 | 43,833 | 26,983 | Upgrade
|
| Research & Development | 56,835 | 42,817 | 38,561 | 32,780 | 1,029 | Upgrade
|
| Other Operating Expenses | 793.02 | 872.25 | 733.32 | 760.94 | 690.81 | Upgrade
|
| Operating Expenses | 124,617 | 129,168 | 117,150 | 90,590 | 31,150 | Upgrade
|
| Operating Income | -90,322 | -94,970 | -116,944 | -95,807 | 2,844 | Upgrade
|
| Interest Expense | -1,007 | -631.84 | -9,906 | -21,764 | -5,231 | Upgrade
|
| Interest & Investment Income | 4,861 | 3,683 | 3,031 | 2,206 | 10,933 | Upgrade
|
| Earnings From Equity Investments | - | - | -1,210 | -1,734 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 761.97 | 30.76 | -113.93 | -44.53 | -466.78 | Upgrade
|
| Other Non Operating Income (Expenses) | -11,780 | -428.55 | 22,216 | -379.06 | -35,343 | Upgrade
|
| EBT Excluding Unusual Items | -97,486 | -92,316 | -102,926 | -117,523 | -27,264 | Upgrade
|
| Gain (Loss) on Sale of Investments | 303 | 341.93 | -3,244 | -9,036 | -11,605 | Upgrade
|
| Gain (Loss) on Sale of Assets | -201.14 | 30.3 | -235.89 | -287.07 | -3.45 | Upgrade
|
| Asset Writedown | -801.87 | -2,271 | -9,162 | -223.61 | -241.5 | Upgrade
|
| Other Unusual Items | -503.07 | -1,024 | -42.95 | 7,728 | -2.67 | Upgrade
|
| Pretax Income | -98,689 | -95,239 | -115,611 | -119,341 | -39,117 | Upgrade
|
| Income Tax Expense | 1,687 | 2,044 | 473.8 | -111.74 | -6,448 | Upgrade
|
| Earnings From Continuing Operations | -100,376 | -97,283 | -116,085 | -119,229 | -32,668 | Upgrade
|
| Net Income to Company | -100,376 | -97,283 | -116,085 | -119,229 | -32,668 | Upgrade
|
| Minority Interest in Earnings | 42,296 | 41,664 | 17,428 | 25,309 | -13,822 | Upgrade
|
| Net Income | -58,079 | -55,619 | -98,657 | -93,920 | -46,490 | Upgrade
|
| Net Income to Common | -58,079 | -55,619 | -98,657 | -93,920 | -46,490 | Upgrade
|
| Shares Outstanding (Basic) | 258 | 236 | 201 | 173 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 258 | 236 | 202 | 173 | 57 | Upgrade
|
| Shares Change (YoY) | 9.53% | 16.45% | 16.73% | 206.64% | 24.06% | Upgrade
|
| EPS (Basic) | -225.00 | -236.00 | -490.37 | -541.72 | -822.24 | Upgrade
|
| EPS (Diluted) | -225.00 | -236.00 | -497.41 | -541.72 | -822.24 | Upgrade
|
| Free Cash Flow | -57,662 | -83,669 | -133,101 | -119,132 | 19,957 | Upgrade
|
| Free Cash Flow Per Share | -223.38 | -355.02 | -657.66 | -687.14 | 352.97 | Upgrade
|
| Gross Margin | 22.85% | 22.71% | 0.26% | -19.84% | 26.74% | Upgrade
|
| Operating Margin | -60.17% | -63.07% | -149.26% | -364.35% | 2.24% | Upgrade
|
| Profit Margin | -38.69% | -36.94% | -125.92% | -357.17% | -36.56% | Upgrade
|
| Free Cash Flow Margin | -38.41% | -55.57% | -169.88% | -453.05% | 15.70% | Upgrade
|
| EBITDA | -66,017 | -65,899 | -88,552 | -70,545 | 7,152 | Upgrade
|
| EBITDA Margin | -43.98% | -43.76% | -113.02% | -268.27% | 5.63% | Upgrade
|
| D&A For EBITDA | 24,305 | 29,071 | 28,392 | 25,262 | 4,308 | Upgrade
|
| EBIT | -90,322 | -94,970 | -116,944 | -95,807 | 2,844 | Upgrade
|
| EBIT Margin | -60.17% | -63.07% | -149.26% | - | 2.24% | Upgrade
|
| Advertising Expenses | - | - | - | - | 4,369 | Upgrade
|
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.